564 related articles for article (PubMed ID: 27054905)
1. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem.
Al Yami MS
J Infect Public Health; 2017; 10(6):770-773. PubMed ID: 28209320
[TBL] [Abstract][Full Text] [Related]
3. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
De Waele JJ; Carrette S; Carlier M; Stove V; Boelens J; Claeys G; Leroux-Roels I; Hoste E; Depuydt P; Decruyenaere J; Verstraete AG
Intensive Care Med; 2014 Mar; 40(3):380-7. PubMed ID: 24356862
[TBL] [Abstract][Full Text] [Related]
5. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
6. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
7. Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.
Jensen JU; Hein L; Lundgren B; Bestle MH; Mohr T; Andersen MH; Løken J; Tousi H; Søe-Jensen P; Lauritsen AØ; Strange D; Petersen JA; Thormar K; Larsen KM; Drenck NE; Helweg-Larsen J; Johansen ME; Reinholdt K; Møller JK; Olesen B; Arendrup MC; Østergaard C; Cozzi-Lepri A; Grarup J; Lundgren JD;
Crit Care Med; 2015 Mar; 43(3):594-602. PubMed ID: 25493970
[TBL] [Abstract][Full Text] [Related]
8. Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
Lheureux O; Trepo E; Hites M; Cotton F; Wolff F; Surin R; Creteur J; Vincent JL; Gustot T; Jacobs F; Taccone FS
Liver Int; 2016 Jul; 36(7):1002-10. PubMed ID: 26645828
[TBL] [Abstract][Full Text] [Related]
9. Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Kobayashi R; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
J Microbiol Immunol Infect; 2018 Aug; 51(4):473-477. PubMed ID: 28690028
[TBL] [Abstract][Full Text] [Related]
10. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
11. Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
Peyko V; Smalley S; Cohen H
J Pharm Pract; 2017 Apr; 30(2):209-213. PubMed ID: 26912532
[TBL] [Abstract][Full Text] [Related]
12. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
[TBL] [Abstract][Full Text] [Related]
13. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
Sano H; Kobayashi R; Suzuki D; Hori D; Kishimoto K; Kobayashi K
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27873451
[TBL] [Abstract][Full Text] [Related]
15. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
16. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
[TBL] [Abstract][Full Text] [Related]
17. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
18. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis.
Liu TJ; Lam JP
Am J Health Syst Pharm; 2012 Jul; 69(13):1109. PubMed ID: 22722588
[No Abstract] [Full Text] [Related]
19. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
20. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
